School of Medicine


Showing 1-8 of 8 Results

  • Angelle Desiree LaBeaud

    Angelle Desiree LaBeaud

    Professor of Pediatrics (Infectious Diseases), Senior Fellow at the Woods Institute for the Environment and Professor, by courtesy, of Epidemiology and Population Health and at the Stanford Doerr School of Sustainability

    Current Research and Scholarly InterestsArthropod-borne viruses are emerging and re-emerging infections that are spreading throughout the world. Our laboratory investigates the epidemiology of arboviral infections, focusing on the burden of disease and the long-term complications on human health. In particular, Dr. LaBeaud investigates dengue, chikungunya, and Rift Valley fever viruses in Kenya, where outbreaks cause fever, arthritis, retinitis, encephalitis, and hemorrhagic fever. Our main research questions focus on the risk factors for arboviral infections, the development of diagnostic tests that can be administered in the field to quickly determine what kind of arboviral infection a person has, and the genetic and immunologic investigation of why different people respond differently to the same infection. Our long-term goals are to contribute to a deeper understanding of arboviral infections and their long-term health consequences and to optimize control strategies to prevent these emerging infections. Our laboratory also investigates the effects of antenatal and postnatal parasitic infections on vaccine responses, growth, and development of Kenyan children.

    My lab at Stanford supports the field work that is ongoing in Kenya, but we also have several projects that are based locally. We strive to improve diagnostics of arboviral infections and are using Luminex technology to build a new screening assay. We also have created a Luminex based platform to assess vaccine responses against multiple pathogens.

  • Marvin Langston

    Marvin Langston

    Assistant Professor of Epidemiology and Population Health

    BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.

    Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.

    His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.

    Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work.

  • Jennifer Lee

    Jennifer Lee

    Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsI am a clinical scientist (PhD epidemiology), endocrinologist, and CMO at VAPA Cooperative Studies Program Coordinating Center. My group does pattern and prediction mapping along the life-course of interventions/outcomes and how healthcare system can positively impact health longitudinally. We use novel molecular epi, 'big' data like EHRs using multiple designs/methods/technologies. These interests cut across multiple complex chronic diseases and lifespan.
    https://med.stanford.edu/jleelab.html

  • Mary Leonard

    Mary Leonard

    Arline and Pete Harman Professor and Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsMy multidisciplinary research program is focused on (1) the detrimental effects of glucocorticoids, sarcopenia and inflammation on bone development in pediatric diseases, (2) the long-term effects of childhood cancer on bone and muscle quality, (3) the assessment of renal osteodystrophy using novel micro-imaging techniques, (4) the effects of vitamin D deficiency on physical function and cardiovascular disease, and (5) the evaluation of biomechanical interventions as anabolic bone therapies.

  • Eleni Linos, MD, MPH, DrPH

    Eleni Linos, MD, MPH, DrPH

    Associate Dean for Research, Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health

    BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. She is a Professor of Dermatology and Epidemiology at Stanford University. Dr. Linos also serves as an Associate Dean for Research, leading the KL2 Research Training Program.

    Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients. She received her medical degree from Cambridge and Oxford universities in the UK, received a masters and doctoral degree from the Harvard School of Public Health and completed her residency at Stanford.

  • Ying Lu

    Ying Lu

    Professor of Biomedical Data Science and, by courtesy, of Epidemiology

    Current Research and Scholarly InterestsBiostatistics, clinical trials, statistical evaluation of medical diagnostic tests, radiology, osteoporosis, meta-analysis, medical decision making

  • Stephen Luby

    Stephen Luby

    Lucy Becker Professor of Medicine, Senior Fellow at the Woods Institute for the Environment, Freeman Spogli Institute for International Studies and Professor, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsDr. Luby’s research interests include identifying and interrupting pathways of infectious disease transmission in low income countries.